🇺🇸 FDA
Patent

US 7211252

Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

granted A61KA61K38/00A61P

Quick answer

US patent 7211252 (Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists) held by The Board of Regents of the University of Texas System expires Mon Apr 26 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue May 01 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 26 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/00, A61P, A61P19/00, A61P19/08